CPA
TCRT icon

Cowen Prime Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Cowen Prime Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-21
Closed -$20K – 188
2017
Q2 		$20K Hold
21
– – 0.01% 159
2017
Q1 		$20K Hold
21
– – 0.01% 161
2016
Q4 		$17K Hold
21
– – 0.01% 161
2016
Q3 		$18K Hold
21
– – 0.01% 197
2016
Q2 		$18K Buy
+21
New +$22.9K 0.01% 177

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cowen Prime Advisors's TCRT Position: Q3 2017 in Review

Cowen Prime Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2017, closing a stake of 21 shares — an estimated $20K sold.

Cowen Prime Advisors first reported a position in TCRT in Q2 2016 and held it in 5 quarters. The position peaked at $20K in Q2 2017. 122 funds tracked by Wall St. Rank hold TCRT as of Q3 2017.

  • Cowen Prime Advisors reported no remaining Alaunos Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Cowen Prime Advisors sold 21 Alaunos Therapeutics shares in Q3 2017, an estimated $20K.
  • Cowen Prime Advisors first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 5 quarters.
  • Cowen Prime Advisors's Alaunos Therapeutics position peaked at $20K in Q2 2017.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2017.

Based on Cowen Prime Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.